. Author manuscript; available in PMC: 2023 Feb 1.

Published in final edited form as: Aliment Pharmacol Ther. 2021 Dec 21;55(3):277–291. doi: 10.1111/apt.16741

Table 3.

Clinical trials of S1PR modulators

Name	Clinical trials			FDA Approvals	REF (ClinicalTrials.gov number)
Name	UC	CD	Non-IBD	FDA Approvals	REF (ClinicalTrials.gov number)
Ozanimod	Phase III, completed	Phase III, recruiting	Phase III in MS, completed	MS, 2020; UC, 2021	NCT02294058, NCT01628393, NCT02047734, NCT02435992, NCT03467958, NCT03440385, NCT03440372, NCT03464097, and others.
Etrasimod	Phase III, recruiting; Phase III, active	Phase II and III, recruiting	Phase II in Eosinophilic Esophagitis, recruiting; Phase II in Atopic Dermatitis, active	None	NCT04706793, NCT04176588, NCT03945188, NCT04173273, NCT04682639, NCT04162769, and others
Amiselimod	None	Phase II, completed	Phase II in Plaque Psoriasis, completed; Phase II in SLE, completed	None	NCT02378688, NCT02389790, NCT01987843, NCT02307643
KRP-203	Phase II, Terminated	None	Phase II in Subacute Cutaneous Lupus Erythematosus, completed	None	NCT01375179, NCT01294774
Fingolimod	None	None	Phase III in MS, completed	RRMS, 2010	NCT00289978
Siponimod	None	None	Phase III in SPMS, completed; Phase III in MS, recruiting; Phase II in Active Dermatomyositis.	None	NCT01665144, NCT03623243, NCT02029274
Ponesimod	None	None	Phase III in MS, completed; Phase II in Psoriasis, completed	None	NCT02425644, NCT01208090
Cenerimod	None	None	Phase II in SLE, completed	None	NCT02472795

CD, Crohn’s disease; FDA, Food and Drug Administration; MS, multiple sclerosis; RRMS, relapsing–remitting multiple sclerosis; SLE, systemic lupus erythematosus; UC, ulcerative colitis